Comparison of cfDNA content in different cancer types with different extraction methods.

Authors

null

Wenlong Zhang

Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China

Wenlong Zhang , Yanan Zhao , Jun Li , Dan Cong , Di Zhou , Yang Yang , Yuansong Bai , Tianhao Mu , Ming Liu , Yan Yin , Shifu Chen , Yuanyuan Liu

Organizations

Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China, HaploX Biotechnology Co., Ltd., Shenzhen, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co., Ltd., Shenzhen, Guangdong, China

Research Funding

No funding received
None.

Background: ctDNA liquid biopsy technology has been widely used in the whole course of cancer management, from early screening and early diagnosis of tumors to tumor monitoring and medication guidance. However, the performances of ctDNA as a biomarker in these scenarios are different among different cancer types. One possible reason is that different types of cancer release different amounts of ctDNA or cfDNA, therefore, we explored the cfDNA levels in different cancer types in this study. Methods: We collected 15913 peripheral blood samples from 14686 cancer patients with different clinicopathologies, 256 patients with pulmonary nodules, and 971 healthy people. We isolated their plasma and extracted the cfDNA using QIAamp Circulating Nucleic Acid Kit, Apostle MiniMax cfDNA Extraction Kit or HaploX magnetic bead method cfDNA extraction kit. We calculated the average concentration of cfDNA (ng/ml) for different groups. Results: The number of samples of cervical cancer, liver cancer, glioma, colon cancer, prostate cancer, nasopharyngeal carcinoma, gallbladder carcinoma, melanoma, cholangiocarcinoma, colorectal cancer, breast cancer, gastric cancer, endometrial carcinoma, lung cancer, urothelial carcinoma, rectal cancer, ovarian cancer, healthy people, and pulmonary nodule patients are 93, 469, 113, 277, 139, 76, 89, 132, 171, 4010, 407, 547, 68, 7750, 46, 203, 96, 971 and 256, respectively. The cfDNA level of corresponding groups are 88.07, 79.51, 75.57, 63.58, 61.37, 59.09, 57.59, 57.16, 42.67, 34.73, 31.75, 31.37, 31.33, 29.84, 28.72, 28.69, 23.83, 17.82 and 12.54 ng/ml, respectively. The main groups are shown in the table below. Conclusions: The cfDNA concentrations of healthy people or pulmonary nodule patients were significantly lower than that of tumor patients, and there were also significant differences between different types of cancer. What's interesting, the cfDNA concentrations of lung cancer patients, pulmonary nodule patients and healthy people were quite different. What’s more, there were differences between Colon cancer and Rectal cancer patients. So, the cfDNA concentration maybe a good dimention to be used in early cancer screening and tracing of tumor types.

Population typessample sizecfDNA concentration(ng/mL)
Liver cancer46979.51
Colon cancer27763.58
Colorectal cancer401034.73
Breast cancer40731.75
Gastric cancer54731.37
Lung cancer775029.84
Rectal cancer20328.69
Healthy person97117.82
Pulmonary nodule patient25612.54

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e15026)

DOI

10.1200/JCO.2023.41.16_suppl.e15026

Abstract #

e15026

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?

First Author: Sasmith R. Menakuru

Abstract

2022 ASCO Annual Meeting

Incidental pulmonary nodules, lung cancer screening, and lung cancer in the Medicare population.

First Author: Raymond U. Osarogiagbon

Abstract

2023 ASCO Annual Meeting

Prospective evaluation of cell-free DNA fragmentation profiles for lung cancer detection.

First Author: Kwok-Kin Wong